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Abstract: During the climacteric period, several symptoms exist that motivate women to seek 
medical advice; one of the most common is the hot flush, which presents in 75%–85% of these 
during a variable time span. For the treatment of hot flush, several non-hormonal treatments 
exist; among them, veralipride has shown to be a useful treatment of vasomotor symptoms 
during the climacteric period. In recent times, several medical societies have discredited its use. 
The purpose of this review, therefore, is to define a measured position in relation to the use 
of this drug. On completion of this review, it was possible to conclude that this drug has an 
antidopaminergic mechanism of action. The recommended schedule is: 100 mg/day for 20 days, 
with 10 days drug free. Since the risk of undesirable secondary effects such as galactorrhea, 
mastodynia, and extrapyramidal can increase with use, no more than 3 treatment cycles are 
recommended. This drug has a residual effect that can allow drug-free intervals, which permit 
a longer time between schedules.
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Introduction
During the climacteric period, several symptoms exist that motivate women to seek 
medical advice. One of the most frequent is the hot flush, which presents in 75%–85% 
of these for a variable time span.
The hot flush is defined as a sudden hot sensation in the face, neck, and chest, 
which can have different intensity and frequency during the day and night and can be 
accompanied by sweating, flushing, throbs, anxiety, or irritability.1 The hot flush has 
an average duration of 4 minutes but can last from a few seconds to 10 minutes.2
For hot flushes to occur, estradiol serum levels need to have decreased. This 
produces changes in hypothalamic neurotransmitters such as those synthesized in 
noradrenergic and dopaminergic neurons. The increase in noradrenergic tone modifies 
the opioid system and in concert with the decrease in dopaminergic tone modifies the 
release of gonadotrophin-releasing hormone (GnRH) and luteinizing hormone (LH),3 
which traduce an increase in its pulsatility. These neurotransmitters by themselves 
promote instability of the thermoregulatory center and condition vasomotor symptoms.4 
Also, it has been observed that estrogen deficiency is associated with a decrease in 
serotonin levels allowing hot flushes to occur, probably due to an interconnection 
between this neurotransmitter and noradrenaline.5
For the treatment of climacteric symptoms, several drugs have been used with 
different results in relation to their effectiveness and secondary effects.6 The most 
representative studies with these drugs are shown in Table 1.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Veralipride is another drug that has shown its effectiveness, 
and it has been considered a good therapeutic alternative for 
climacteric-related vasomotor symptoms when a contraindication 
or non-acceptance of hormone therapy (HT) exists. Veralipride 
can also be used in association with other drugs that do not con-
fer any control of vasomotor symptoms; for example, raloxifene, 
whose main indication is for postmenopausal women with risk 
of or established osteopenia-osteoporosis.31
Veralipride has been used for a long time. Recent studies 
have proved its efficiency in the recommended dose of 
100 mg/day;32 however, at this time some medical societies33 
and government organizations34 have discredited its use due to 
its secondary adverse effects. The still in use Mexican Official 
Norm for the prevention and control of perimenopausal and 
postmenopausal diseases in women establishes that the drug 
can be useful in the control of vasomotor symptoms.35
Table 1 Hot flushes decrease with several treatments
Mechanism Dose Hot flushes 
decrease vs placebo
Secondary effects Withdrawal (%)
Clonidine 
Carranza-Lira7
α-2 adrenergic 
agonist 0.1 mg e/12 hr 83% vs 50% Mouth dryness, 
depression, nauseas, 
insomnia, somnolence
–
Gabapentin 
Reddy8 
 
Biglia9
GABA analog
900 mg/day 
900 mg/day
54%–71% vs 29
 
Frequency 57.0% 
Intensity 66.9%
Dizziness, headache, 
disorientation up to 50%
– 
 
34.8
Venlafaxine 
evans10 
Phillips11  
Ladd12
SNRI
75 mg/day 
75–225 mg/day
61% vs 20% 
60%
Anti-cholinergic effects 
Hepatitis
– 
– 
–
Desvenlafaxine 
Archer13,14 
 
Speroff15
SNRI
100–150 mg/day 
100 mg/day
63% vs 47% 
66.6% vs 50.8% 
64%
More than placebo 
 
–
Paroxetine 
Stearns16 SSRI 25 mg/day 65% vs 38% –
Fluoxetine 
Loprinzi17 
Oktem18  
Suvanto-Luukonen19
SSRI
20 mg/day 
20 mg/day 
10–30 mg/day
50% vs 36% 
62% 
No better than placebo
– 
33  
34
Citalopram 
Suvanto-Luukonen19
Soares20
Kalay21
SSRI
10–30 mg/day 
20–60 mg/day 
10–20 mg/day
No better than placebo 
86.6% decrease in depression 
37% vs 13%
34 
– 
–
Propranolol
Carranza7
Coope22  
Alcoff23
β adrenergic 
blocker 20 mg e/12 hr
40 mg e/8 hr
50% vs 50%
Similar than placebo 
Favorable vs placebo
– 
– 
–
Vitamin E 
Barton24
 
Biglia25
800 IU/day One hot flush less than 
with placebo 
Frequency 10.2% 
Intensity 7.28%
Clinically similar to 
placebo
– 
 
34.8
Methyil-dopa
Andersen26
Nesheim27
α2 adrenergic 
agonist 375–1125 mg/day 
250–500 e/12hr
65% vs 38% 
85%
– 
33
Cimicifuga  
racemosa 
Oktem18
Jacobson28
Borrelli29
40 mg/day 
Not indicated 
4 mg e/12 hr
85% 
No better than placebo 
Similar to estrogen
33 
Risk of hepatotoxycity30 
–
Abbreviaitons: SSRI, serotonin selective reuptake inhibitors; SNRI, serotonin noradrenalin reuptake inhibitors.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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For all previously exposed the purpose of this work is 
to review the current evidence with veralipride and define a 
measured position without bias in relation to its use.
Pharmacology
Veralipride is a dopaminergic antagonist of receptor D2, whose 
formula is N-[allyl-1 pyrrolidinyl-2) methyl] dimethoxy-2,3-
sulfamoyl-5 benzamide.36 This drug induces prolactin secretion 
without any estrogenic or progestagenic effects. Serum levels of 
follicle stimulating hormone, LH, estradiol, and estrone aren’t modi-
fied.37 However, some studies have reported that LH can decrease. 
Prolactin increase and LH decrease can be explained by a stimula-
tion of endogenous opioid activity.3,38 This drug is well absorbed 
when administered orally, achieving maximal concentrations at 
2.5 hours. It is poorly metabolized and is eliminated in the urine and 
feces. After oral administration, the half-life is 4 hours, and 44% is 
excreted without any changes in urine in the first 120 hours.3
Clinical studies
When evaluating hot flushes, frequency and intensity are taken 
in account. With veralipride, it has been reported that since the 
4th treatment day, hot flushes begin to subside.3 In other studies 
in which veralipride has been compared against placebo, it has 
been reported that there is a statistically significant reduction 
in frequency as well as in intensity of hot flushes after 20 days 
of continuous treatment at a dose of 100 mg/day.3
When comparing veralipride with HT, a decrease in 
frequency of hot flushes of 80% versus 100% and of intensity 
of 71% versus 100%, respectively, has been observed.7
Most of the studies agree that the decrease of hot flushes 
with veralipride use is from 48.0% to 89.9% depending on 
time of use and method of administration.
Several ways of prescribing veralipride have been 
reported and not always in accordance with the product 
directions – many times due to ignorance and others with 
the idea of decreasing the secondary effects such as hyper-
prolactinemia as well as those extrapyramidal.
The schedules in use have different rates of effectiveness 
(Table 2) and secondary effects and are:7,36,39–41
a.  Classic schedule, 100 mg/day for 20 days, with 10 days 
drug free for no more than 6 months;
b.  100 mg/day for 7 days, followed by 100 mg every 
48 hours for 1 month, followed by 100 mg/day twice a 
week for 3–6 months;
c.  100 mg/day from Monday to Friday with Saturday and 
Sunday free of treatment;
d.  100 mg/day for 2 days, and 2 days without treatment, and 
then repeat;
e.  100 mg every 48 hours for 3–6 months.
Leo et al indicate that every veralipride prescription 
schedule must be individualized, and that 6 cycles of treat-
ment are not associated with addiction.3
Secondary effects
One of the main secondary effects of veralipride use is 
hyperprolactinemia, which may or may not be accompanied 
by galactorrhea, and can disappear at 48 hours of treatment 
Table 2 Veralipride efficiency with several evaluated schedules
Schedule N Time Study Results
David36 A 47 2 months Double blind, placebo controlled, 
crossover
Hot flush reduction 80% 
Residual effect 3 months after withdrawal
wesel39  B 40 Double blind, randomized Similar decrease in hot flushes between groups
Melis40 C 40 1 month Randomized, double blind, 
placebo controlled
85% reduction
vercellini41  D 36 2 months Randomized, double blind, 
placebo controlled
Reduction 78% vs placebo 33%
Carranza-Lira7 e 75 3 months Comparative, randomized, 
placebo controlled
80% reduction in frequency, 71% in intensity, 82% 
duration, sweats 66.6% 
Morgante31  F 29 6 months Randomized, comparative without differences between in number of hot 
flushes and Kupperman’s index 
Hot flushes decrease in 63% and 66% at 3rd and 
6th month respectively 
Boukobza42  G 166 3 months Open, multicentric  Hot flush reduction 89.9% 
In 64.5% residual effect 3 months after withdrawal 
vercellini43 H 25 28 days Open, observational trial 92% of patients have decrease in frequency and 
intensity of hot flushes
Marais44 I – 1–14 months Comparative, placebo controlled 48%–72% decrease
Notes: A, 100 mg/day for 20 days and 10 days drug free; B, 100 mg/day for 20 days and 10 days drug free versus conjugated estrogens 1.25 mg/day; C, 100 mg/day; 
D, 100 mg/day; e, 100 mg/day from Monday to Friday; F, Raloxifene plus veralipride in alternate days versus raloxifene and veralipride in alternate months; G, 100 mg/day for 
20 days and 10 days drug free; H, 100 mg/day 20 days.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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withdrawal,39 other studies indicate that the normalization of 
prolactin levels can take 2 or 3 weeks.45 Reported prolactin 
levels after 2 cycles have been 106.2 ± 41.5 ng/mL;39 others 
have reported levels 10 times higher than those at baseline.46 
A clinical study reported that after veralipride administration 
at a dose of 100 mg/day for 6 months on alternate days or 
months, the prolactin levels were not higher than 21 ng/mL.7 
Other reported secondary effects have been galactorrhea, 
headache, nervousness, insomnia, depression, mastodynia, 
and weight increase.
The most serious effects that have been reported with 
veralipride use are those extrapyramidal, such as acute 
dyskinesia, tardive dyskinesia, Parkinsonism, postural 
tremor, myoclonia, and dystonia. Many of these have been 
related to over-dosage and due to the lack of prescription 
instruction follow-up; however, this it is not always the 
case.10,42,46,47 See Table 3.
It’s worth mentioning that the Pharmacovigilance commit-
tee from the laboratory that produces this drug in Mexico has 
reported that sales in 5 years have been 2,265,729 pieces. In 
this time they have been informed of only 35 adverse effects. 
Of these, 21 have been attributed to incorrect medication use: 
anxiety (6), depression (6), abnormal movements (2), weight 
gain (2), lower limb pain (2), neck rigidity (1), galactorrhea 
(1), and muscular weakness (1). Those which presented after 
adequate drug intake numbered 14: insomnia (3), nervousness 
(2), fear (2), fine tremor (1), irritability (1), lack of appetite (1), 
mastitis (1), galactorrhea (1), pain (1), and head pain (1).52
Contraindications and prescription 
recommendations
After the review of several non-hormonal options for the treat-
ment of climacteric hot flushes it can be concluded that for 
a drug to be considered as a good option for the treatment of 
vasomotor symptoms, an evaluation of the risk-benefit of the 
chosen therapy is always needed, and this must be well sup-
ported by clinical studies that evaluate safety parameters.53
Those women than can be candidates for veralipride use 
must achieve an adequate clinical profile, which means they 
will lack any history of tardive dyskinesia, Parkinsonism, 
acute dyskinesia, postural tremor, myoclonia, dystonia, 
hyperprolactinemia, breast fibrocystic disease, depression, 
and breast cancer.37
Conclusion
After this review it can be concluded that veralipride is a 
good option, and a safe drug if recommended doses are 
respected.3 Its high effectiveness in the control of vaso-
motor symptoms allows a high number of patients to be 
benefited.
The presentation of secondary adverse events is decreased 
using this medicament at a dose no greater than 100 mg/day, 
for short time spans, and leaving drug-free intervals between 
schedules. The drug-free intervals will not decrease drug 
favorable effects due to the drug’s residual effect as shown 
before.
It’s worth investigating safety aspects in the Latin-
  American population as well as the use of low-dose. 
Recently, the Mexican Association for the Study of the 
Climacteric, gave the following recommendations when 
veralipride is prescribed.
Table  3  Secondary  effects  with  veralipride  use,  according  to 
schedule
Secondary effect Schedule N or %
David36 Depression+ 100 mg/day 20 days  
and 10 days drug free
19%–47%
Boukozoba42 Breast tenderness 
Insomnia 
Mouth dryness 
Somnolence 
Digestive problems 
Dizziness 
weakness
100 mg/day 20 days  
and 10 days drug  
free for 3 months
1.2% 
0.6% 
0.6% 
1.2% 
0.6% 
0.6% 
0.6%
Masmoudi46 Parkinsonism 
Acute dyskinesia 
Parkinsonism plus  
other in 8 cases 
Tardive dyskinesia 
Postural tremor 
Myoclonia 
Dystonia
Several schedules N
15
2 
 
6
3
1
1
Montemurro47 Acute coronary  
syndrome
100 mg/day 1
Kunhardt48 Pyrosis 
Hair fall 
Mamary pruritus 
Mastodynia 
Placebo 
Headache, joint  
pain, vaginal  
discharge  
mastodynia 1/e
100 mg/day 20 days  
and 10 days drug free
1
1
1
3
 
1 each
Raja49 Tardive dyskinesia Not reported 1
Sining50 Dystonia 
(Hypertension  
under enalapril  
treatment)
100 mg/day  
(2 months)
1
Teive51 Increase in  
Parkinsonian  
symptoms
Not reported 1Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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1.  An evaluation of medical history must be carried out, 
following a strict selection profile according to medical 
history, particularly of neuropsychiatric problems.37,46
2.  Respect the schedule and dose indicated by producer (20 
treatment days with 10 days drug free).37,46,53
3.  Don’t give more than 3 treatment cycles together, and 
don’t repeat more than twice in a year (no more than 
6 cycles per year).3
4.  In those women with chronic use, the drug must be gradu-
ally withdrawn to avoid withdrawal symptoms.3,38,53
Disclosure
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